贝前列腺素钠对T2DM肾小球硬化老年患者Scr BUN FIB D-D TNF-α hs-CRP的影响

Effects of Beraprost Sodium on Scr BUN FIB D-D TNF-alpha,hs-CRP in Elderly Patients with Glomerulosclerosis of T2DM

目的:探讨贝前列腺素钠对老年2型糖尿病(T2DM)肾小球硬化患者血清炎症因子、凝血功能和肾功能的影响。方法:选取本院2016年1月至2019年1月收治的78例老年T2DM肾小球硬化患者,采用随机抽样法,随机分为对照组(给予贝那普利治疗)和研究组(给予贝那普利+贝前列腺素钠治疗),两组各39例。比较两组患者治疗前后血清炎症因子超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)和凝血功能指标D-二聚体(D-D)、纤维蛋白原(Fib)及肾功能指标血尿素氮(BUN)、血肌酐(SCr)水平的差异。结果:相比治疗前,两组患者治疗后2个月hs-CRP和TNF-α的含量均显著下降(P<0.05);相比对照组,研究组治疗后2个月hs-CRP和TNF-α的含量均显著下降(P<0.05)。对照组治疗后2个月D-D和Fib浓度与治疗前比较,并无明显变化(P>0.05);研究组治疗后2个月D-D和Fib浓度较治疗前均显著下降(P<0.05),且较对照组治疗后的水平均显著下降(P<0.05)。两组患者治疗后2个月BUN和SCr的水平较治疗前均显著下降,且研究组治疗后BUN和SCr的水平较对照组治疗后显著下降(P<0.05)。结论:在常规治疗基础上,应用贝前列腺素钠治疗可有效改善老年T2DM肾小球硬化患者凝血功能和肾功能,调节体内炎症因子的水平,具有显著的治疗效果,因此值得临床应用。

Objective:To investigate the effects of beraprost sodium on serum inflammatory factors, coagulation function and renal function in elderly patients with type 2 diabetes mellitus (T2DM) with glomerulosclerosis. Methods: 78 elderly patients with T2DM glomerulosclerosis admitted to our hospital from January 2016 to January 2019 were randomly divided into control group (treated with benazepril) and research group (treated with benazepril and beraprost sodium), 39 cases in each group by convenient sampling. The levels of serum inflammatory factor hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), coagulation function index D-dimer (D-D), fibrinogen (Fib) and renal function index blood urea nitrogen (BUN) and serum creatinine (SCr) were compared between the two groups before and after treatment. Results: Compared with before treatment, the contents of hs-CRP and TNF-α in the two groups decreased significantly 2 months after treatment (P<0.05);Compared with the control group, the contents of hs-CRP and TNF-α in the study group decreased significantly 2 months after treatment (P<0.05). The concentration of D-D and Fib in the control group did not change significantly after 2 months of treatment compared with that before treatment (P>0.05);The concentration of D-D and Fib in the study group decreased significantly after 2 months of treatment compared with that before treatment (P<0.05), and decreased significantly after treatment compared with that in the control group (P<0.05). The levels of BUN and SCr in the two groups were significantly lower than those before treatment, and the levels of BUN and SCr in the study group were significantly lower than those in the control group after treatment (P<0.05). Conclusion: Beraprost sodium therapy can effectively improve the coagulation function and renal function of elderly patients with glomerulosclerosis of type 2 diabetes mellitus on the basis of routine treatment, and regulate the level of inflammatory factors in vivo. It has significant therapeutic effect, so it is worthy of clinical application.